EDN1 and Gitelman syndrome: Physiological Rho-kinase agonists mediate vascular inflammation, which include cell-adhesion molecules, ET-1, platelet-derived growth factor, sphingosine-1-phosphate, shear, and mechanical stress.40,41 Interestingly, patients with Bartter's or Gitelman's syndrome have increased ACE2 and blunted Rho-kinase responses, and these patients appear to have an innate resistance to SARS-CoV-2 infection.42,43